ATE536877T1 - 7-keto-dhea zur anwendung in der psychiatrie - Google Patents

7-keto-dhea zur anwendung in der psychiatrie

Info

Publication number
ATE536877T1
ATE536877T1 AT08798637T AT08798637T ATE536877T1 AT E536877 T1 ATE536877 T1 AT E536877T1 AT 08798637 T AT08798637 T AT 08798637T AT 08798637 T AT08798637 T AT 08798637T AT E536877 T1 ATE536877 T1 AT E536877T1
Authority
AT
Austria
Prior art keywords
agents
psychiatric
disorders
dhea
keto
Prior art date
Application number
AT08798637T
Other languages
English (en)
Inventor
Sharon Sageman
Richard P Brown
Original Assignee
Sharon Sageman
Richard P Brown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sharon Sageman, Richard P Brown filed Critical Sharon Sageman
Application granted granted Critical
Publication of ATE536877T1 publication Critical patent/ATE536877T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08798637T 2007-09-07 2008-08-25 7-keto-dhea zur anwendung in der psychiatrie ATE536877T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/851,761 US8124598B2 (en) 2006-09-14 2007-09-07 7-keto DHEA for psychiatric use
PCT/US2008/074229 WO2009032600A1 (en) 2007-09-07 2008-08-25 7-keto dhea for psychiatric use

Publications (1)

Publication Number Publication Date
ATE536877T1 true ATE536877T1 (de) 2011-12-15

Family

ID=40029291

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08798637T ATE536877T1 (de) 2007-09-07 2008-08-25 7-keto-dhea zur anwendung in der psychiatrie

Country Status (4)

Country Link
US (1) US8124598B2 (de)
EP (1) EP2197450B1 (de)
AT (1) ATE536877T1 (de)
WO (1) WO2009032600A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124598B2 (en) 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
US20110086828A1 (en) * 2009-10-07 2011-04-14 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Treatment of alcohol abuse and alcoholism using modulators of neurosteroid binding sites on gabaa receptors
US8930222B2 (en) * 2010-08-05 2015-01-06 Abbott Laboratories Method and system for managing patient healthcare
US20140255524A1 (en) * 2013-03-08 2014-09-11 Pipeline Nutrition, Inc. Alpha-gpc dietary supplements for weight loss and/or increasing or maintaining lean body mass
KR102542842B1 (ko) 2016-09-22 2023-06-14 알란 비. 캐쉬 Pms의 증상을 완화하는 방법

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4835147A (en) 1987-05-06 1989-05-30 City Of Hope Dehydroepiandrosterone therapy for ameleoration of prostate hypertrophy and sexual dysfunction
US4891223A (en) 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
DE3889220T2 (de) * 1987-12-25 1994-11-24 Citizen Watch Co Ltd Zeigerbenutzende anzeige.
IT1237904B (it) 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
US5707983A (en) 1990-08-29 1998-01-13 Humanetics Corporation Treatment of alzheimer's disease and modulation of immune system with Δ5-androstenes
US5641766A (en) 1990-08-29 1997-06-24 Humanetics Corporation UP-regulation of immune system with Δ 5-Androstenes
US5585371A (en) 1990-08-29 1996-12-17 Humanetics Corporation Treatment of immune system with Δ5-androstenes
US5603956A (en) 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
CA2041774C (en) 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
US5326570A (en) 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US5925564A (en) 1991-11-06 1999-07-20 Baylor College Of Medicine Expression vector systems and method of use
US5792751A (en) 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
US5705585A (en) 1993-06-30 1998-01-06 Arqule, Inc. Aminimide-containing molecules and materials as molecular recognition agents
GB9215043D0 (en) 1992-07-15 1992-08-26 Flow Inc K Fluid mass flow meters
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
WO1994018955A1 (en) 1993-02-22 1994-09-01 Alza Corporation Compositions for oral delivery of active agents
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5397574A (en) 1993-10-04 1995-03-14 Andrx Pharmaceuticals, Inc. Controlled release potassium dosage form
WO1995011042A1 (fr) 1993-10-21 1995-04-27 Hisamitsu Pharmaceutical Co., Inc. Composition administree par voie nasale et preparation contenant celle-ci
US5399358A (en) 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
US5419917A (en) 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5458888A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5399359A (en) 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
JP4157969B2 (ja) 1994-03-18 2008-10-01 スパーナス ファーマシューティカルズ インコーポレイテッド 乳化薬物送達システム
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US6159445A (en) 1994-07-20 2000-12-12 Nycomed Imaging As Light imaging contrast agents
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US6103263A (en) 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
US5985353A (en) 1994-12-01 1999-11-16 University Of Massachusetts Lowell Biomolecular synthesis of quantum dot composites
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
FR2729295A1 (fr) 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US5686113A (en) 1995-03-21 1997-11-11 Temple University Of The Commonwealth System Of Higher Education Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
FR2732218B1 (fr) 1995-03-28 1997-08-01 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
ES2177592T3 (es) 1995-07-05 2002-12-16 Europ Economic Community Nanoparticulas biocompatibles y biodegradables para la absorcion y administracion de medicamentos proteinicos.
US6217864B1 (en) 1996-02-23 2001-04-17 The Regents Of The University Of California Method for targeted degradation of intracellular proteins in vivo or ex vivo
JP2000510582A (ja) 1996-04-25 2000-08-15 ゼニコン・サイエンシーズ・コーポレーション 微粒子標識を使用した分析物アッセイ
WO1997049387A1 (en) 1996-06-27 1997-12-31 G.D. Searle And Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US6323989B1 (en) 1996-07-19 2001-11-27 E Ink Corporation Electrophoretic displays using nanoparticles
US6361944B1 (en) 1996-07-29 2002-03-26 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
FR2754822B1 (fr) 1996-10-18 1998-11-27 Rhone Poulenc Rorer Sa Polypeptides comprenant des domaines de la proteine gax, impliques dans la repression de transcription et/ou interagissant avec d'autres proteines, acides nucleiques correspondants et leurs utilisations
AU721653B2 (en) 1996-10-25 2000-07-13 Supernus Pharmaceuticals, Inc. Soluble form osmotic dose delivery system
US5837379A (en) 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
JP4209471B2 (ja) 1997-02-20 2009-01-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プラズモン共鳴粒子、方法、および装置
CA2216215A1 (en) 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
AU7706598A (en) 1997-05-30 1998-12-30 Laboratorios Phoenix U.S.A., Inc. Multi-layered osmotic device
US5885616A (en) 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US6187559B1 (en) 1997-08-28 2001-02-13 Novartis Ag Phospholipase D gene
CA2301587C (en) 1997-08-29 2008-07-08 Corixa Corporation Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
AU9509798A (en) 1997-09-25 1999-04-12 University Of Florida Antisense oligonucleotide compositions targeted to angiotensi n converting enzy me mrna and methods of use
US6002817A (en) 1997-09-29 1999-12-14 The Regents Of The University Of Michigan Optical sensors for the detection of nitric oxide
DE19745950A1 (de) 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
US6149868A (en) 1997-10-28 2000-11-21 The Penn State Research Foundation Surface enhanced raman scattering from metal nanoparticle-analyte-noble metal substrate sandwiches
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US5916595A (en) 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
US6265546B1 (en) 1997-12-22 2001-07-24 Genset Prostate cancer gene
WO1999037814A1 (en) 1998-01-22 1999-07-29 Luminex Corporation Microparticles with multiple fluorescent signals
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6395253B2 (en) 1998-04-23 2002-05-28 The Regents Of The University Of Michigan Microspheres containing condensed polyanionic bioactive agents and methods for their production
US6086881A (en) 1998-05-15 2000-07-11 Children's Medical Center Corp. Spatially aligned conjugated composition having a thioether bond linkage
WO2000002950A1 (en) 1998-07-13 2000-01-20 Expression Genetics, Inc. Polyester analogue of poly-l-lysine as a soluble, biodegradable gene delivery carrier
US6262129B1 (en) 1998-07-31 2001-07-17 International Business Machines Corporation Method for producing nanoparticles of transition metals
US6106862A (en) 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
US6099862A (en) 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6333051B1 (en) 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
US6306610B1 (en) 1998-09-18 2001-10-23 Massachusetts Institute Of Technology Biological applications of quantum dots
WO2000029829A1 (en) 1998-11-16 2000-05-25 California Institute Of Technology Simultaneous determination of equilibrium and kinetic properties
US6217901B1 (en) 1999-05-25 2001-04-17 Alnis, Llc Liposome-assisted synthesis of polymeric nanoparticles
GB0003524D0 (en) 2000-02-15 2000-04-05 Btg Int Ltd Cytoprotective steroids (II)
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6368617B1 (en) 2001-05-15 2002-04-09 Reliv' International, Inc. Dietary supplement
WO2004075832A2 (en) 2003-02-27 2004-09-10 Lucas John M Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
US7266051B2 (en) * 2003-05-20 2007-09-04 Timex Group B.V. Method and construction for autocalibrating an actuation mechanism in an electronic device
CN1552331A (zh) * 2003-06-04 2004-12-08 中国医学科学院基础医学研究所 化合物7-羰基表雄酮对慢性轻度应激balb/c小鼠抑郁症的改善作用
US20040248861A1 (en) * 2003-08-29 2004-12-09 Kneller Bruce W. Modified delta5-androstenes having improved bioavailability
US20050069593A1 (en) * 2003-09-29 2005-03-31 Life Time Fitness, Inc. Nutritional supplement containing 7-Keto-DHEA and conjugated linoleic acid
US20050089541A1 (en) 2003-10-23 2005-04-28 L'oreal Chlorhexidine-containing O/W emulsion
US20060004076A1 (en) * 2004-06-30 2006-01-05 Inflabloc Pharmaceuticals, Inc. Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation
US8124598B2 (en) 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20100160274A1 (en) 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use

Also Published As

Publication number Publication date
US8124598B2 (en) 2012-02-28
US20080070879A1 (en) 2008-03-20
WO2009032600A1 (en) 2009-03-12
EP2197450A1 (de) 2010-06-23
EP2197450B1 (de) 2011-12-14

Similar Documents

Publication Publication Date Title
CL2011000488A1 (es) Compuestos derivados de pirazolo-pirimidinas sustituidas; composicion y combinacion farmaceutica que los comprenden; y su uso como inhibidores de pde9 para el tratamiento, alivio y/o prevencion de deterioros cognitivos relacionados con la percepcion, alzheimer,trastornos del sueño, trastorno bipolar, diabetes mellitus.
ATE536877T1 (de) 7-keto-dhea zur anwendung in der psychiatrie
CL2012001673A1 (es) Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras.
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
CL2008001465A1 (es) Compuestos derivados de [2,1,3]benzoxadiazol-5-carboxamidas, moduladores de los receptores ampa; composiciones farmacéuticas; y su uso en el tratamiento de afecciones hipoglutamatérgicas, trastornos cognitivos, enfermedad de parkinson, adhd, síndrome de rett, depresión respiratoria, síndrome x frágil y enfermedad de alzheimer.
CL2008000434A1 (es) Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
CL2011000144A1 (es) Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros.
MX2010003865A (es) Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
MX2009002496A (es) Combinaciones que contienen un derivado de 4-acilaminopiridina.
ECSP11010975A (es) Método de uso de una cepa de bacillus subtilis para mejorar la salud de animales
DE602005018763D1 (de) Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
CL2010001159A1 (es) Compuestos derivados de 3,8-diazabiciclo[2.4.0]octano y 3,6-diazabiciclo[3.2.0]heptano disustituidos, moduladores del receptor de orexina; composicion farmaceutica; utiles en el tratamiento de trastornos del sueño, trastornos metabolicos, entre otros.
WO2012165831A3 (ko) 스트레스 완화 및 진정 효과를 갖는 향료 조성물 및 이를 함유하는 화장료 조성물
CL2007003065A1 (es) Compuestos derivados de benzodioxano, agonista 5ht2c, composicion farmaceutica que lois comprende; y sus uso en el tratamiento de un trastorno psicotico, ansiedad, depresion, trastorno bipolar, sindrome premenstrual, entre otros
CR20110042A (es) Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo [1,4]dioxin-2-ilmetil)-sulfamida
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
CO6551683A2 (es) Tratamiento para trastornos gastrointestinales
BR112012025017A2 (pt) métodos para melhorar a qualidade do sono.
GT200800138A (es) Combinacion de un inhibidor de acetilcolinesterasa y un agonista de 5-ht6 para el tratamiento de disfuncion cognitiva
CL2008002247A1 (es) Compuestos derivados de fenil amida; proceso de preparacion; composicion farmaceutica que los contiene; y su uso en la preparacion de medicamentos para el tratamiento de trastornos del sueno, narcolepsia y trastornos psiquiatricos, entre otros.
MY157192A (en) Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
ATE459353T1 (de) Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
CL2012000097A1 (es) Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros.